IGF1R and geroderma osteodysplastica: Patients affected with moderate-to-severe and active GO are generally treated with high dose intravenous glucocorticoids (ivGCs), orbital radiotherapy, surgical procedures (3) as well as new medications, including Rituximab, an anti-CD20 monoclonal antibody (4), Teprotumumab, an anti-insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (5, 6), Tocilizumab, an interleukin 6 (IL-6) receptor antagonist (7) and mycophenolate (8).